key: cord-1046848-c5v51ie0
authors: Gisondi, P; PIaserico, S; Bordin, C; Alaibac, M; Girolomoni, G; Naldi, L
title: Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update
date: 2020-06-25
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16774
sha: b6f9488bdbe0b8845f70a299a415b6663953fa23
doc_id: 1046848
cord_uid: c5v51ie0

On March 11(th), 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID‐19) a global pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 virus). A consistent number of case reports and clinical series have been already published describing a complex spectrum of skin manifestations associated with the SARS‐CoV‐2 infection. We carried out a review of the English‐language literature up to May 20th 2020, reporting original cases or case series of the cutaneous manifestations of SARS‐CoV‐2 virus infection. The following databases were consulted PubMed, Embase, Google Scholar, ResearchGate. The search of papers was conducted by using the key term ‘COVID‐19’ or ‘SARS‐CoV‐2’ or ‘coronavirus’ combined with each of the following: ‘skin’, ‘cutaneous’, ’dermatologic’ or ‘dermatology’, ‘manifestation’, ‘lesions,’ or ‘rash.’ The patterns of dermatological manifestations associated with SARS‐CoV‐2 infection could be classified into four categories: exanthema (varicella‐like, papulo‐vesicular and morbilliform rash), vascular (chilblain‐like, purpuric/petechial and livedoid lesions), urticarial and acro‐papular eruption. Lastly, other skin manifestations to be considered are the cutaneous adverse reactions to the drugs prescribed for the treatment of COVID‐19. Whether SARS‐CoV‐2 infection can directly cause a worsening of chronic inflammatory diseases such as psoriasis or atopic dermatitis remains to be determined. Dermatology’s outlook in the COVID‐19 pandemic is multidimensional.

On March 11 th , 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID-19) a global pandemic. 1 The disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) was firstly identified in Wuhan, China, in December 2019 and with a rapid evolving scenario has become a serious threat to global public health. 2 As of May 20th, 2020, more than 4,900,000 cases of COVID-19 have been reported, with more than 320,000 deaths. Transmission of SARS-CoV-2 mainly occurs in households and other close settings, including nosocomial ones. The virus enters the body through mucosal surfaces via droplets, aerosols or hand contact. Disease presentation can range from no symptoms to acute respiratory distress syndrome (ARDS), multiple organ failure and death. The most common symptoms include fever, dry cough, fatigue, sputum production, shortness of breath, loss of smell and taste, conjunctivitis. Severe disease is characterised by dyspnoea, blood oxygen desaturation, respiratory failure and venous thromboembolism. 2 

We carried out a review of the English-language literature up to May 20th, 2020, related to the cutaneous manifestation of SARS-CoV-2 virus infection. The following databases were consulted PubMed, Embase, Google Scholar, ResearchGate. The research of articles was conducted by using the key term 'COVID-19' or 'SARS-CoV-2' or 'coronavirus' combined with each of the following: 'skin', 'cutaneous', 'dermatologic' or 'dermatology', 'manifestation', 'lesions,' or 'rash.' For each article, the clinical pattern, type of elementary lesions, localization, early or late onset, age, associated symptoms and number of cases reported were collected.

This article is protected by copyright. All rights reserved

The patterns of dermatological manifestations associated with SARS-CoV-2 infection are reported in Table 1 . The cutaneous manifestations could be classified into the following patterns: exanthema (varicella-like, papulo-vesicular, and morbilliform rash), vascular (chilblain-like, purpuric/petechial and livedoid lesions), urticarial and acro-papular eruption. Each pattern is described below.

The varicella-like exanthema was firstly described by Marzano et al. 13 and Galván Casas 14 et al. as a specific COVID-19-associated skin manifestation. It is clinically characterised by widespread monomorphic papulo-vesicular lesions. In the recent prospective nationwide study conducted in Spain 14 this exanthema was described in 9% of the 375 patients studied. The lesions appear at a median of 3 days after symptoms, and last for a median time of 8 days. It is associated with moderate disease severity generally in middle-aged patients. Trunk is constantly involved, and itching is reported in some, but not all patients.

Histology shows vacuolar degeneration with disorganized keratinocytes, enlarged and multinucleate keratinocytes with dyskeratotic (apoptotic) cells. A dense inflammatory infiltrate may be present.

A maculo-papular rash, defined also as morbilliform, presenting clinical features that resemble typical viral exanthemas has been also described in COVID-19 patients. [15] [16] [17] [18] It appears concomitantly with the other symptoms of infection, lasts for a short period (3-10 days), and itching is reported in most of the patients. It is associated with severe disease in older patients. Galvan Casa et al. 14 reported a prevalence of 47% among their 375 patients. They described a perifollicular distribution in some cases and occasionally scaling. The erythematous rash may be particularly accentuated on the antecubital fossa and axillary folds. 19 Skin biopsy shows some non-specific features of viral-related exanthema, such as slight spongiosis and mild perivascular lymphocytic infiltrate.

This article is protected by copyright. All rights reserved receptor, which is expressed in several tissues, including endothelial cells. 23 The spectrum of the above mentioned vascular lesions may be due to different possibly overlapping mechanisms, including a direct action of the virus on endothelial cells, 24 an indirect effect involving the triggering of immune or autoimmune reactions as in the case of the immune thrombocytopenic purpura, or to an exaggerated and uncontrolled host response accompanying the well known "cytokine storm." Whatever the starting mechanism, the consequent microvascular disfunction can lead to increased vasoconstriction and organ ischemia, inflammation and a further pro-coagulation state. If skin lesions such as chilblain-like lesions correlate with involvement of internal organs remains to be defined.

Chilblain-like or perniosis-like skin lesions present as erythematous-oedematous manifestations affecting acral sites, mostly toe and soles, with possible bullous evolution.

They are usually asymmetrical and mostly itchy and/or painful. 25 They typically affect young patients in the absence of systemic symptoms or associated with low-grade disease severity. Notably, they lack a history of chilblains or Raynaud phenomenon. In the case series reported by Recalcati the eruptions resolved after 2-4 weeks without any treatment. 26 Bouaziz et al. described chilblain like lesions in two patients, one presenting also Raynaud's phenomenon. 27 A 19% prevalence of chilblain-like lesions was documented in the Spanish series. 14 Histology shows a superficial and deep angiocentric and eccrinotropic lymphocytic infiltrate with some papillary dermal edema, vacuolar degeneration of the basal layer and lymphocytic exocytosis to the epidermis and

This article is protected by copyright. All rights reserved acrosyringia. 14 A puzzling finding in patients with chilblain-like lesions is the low percentage of positivity to PCR for SARS-CoV-2. In one study on children and adolescents, only 1 of 19 patients was tested positive. 28 In a similar study on mostly paediatric patients, none of the 19 tested patients resulted positive. 29 This could be explained by the likely lower sensitivity of PCR for SARS-CoV-2 in mild cases and in children, possibly because of a low viral load. 30 Otherwise, chilblain-like lesions could represent a late event in the disease course and PCR could become negative when assessed.

A wide spectrum of purpuric and petechial lesions has been described as possible manifestations associated with SARS-CoV-2 infection. They appear at any time during the COVID-19 course, they are localized on the trunk, buttock, limbs, typically in adult patients and could be associated with symptoms such as a burning sensation. These lesions may cause difficulties with differential diagnosis. Indeed, in Thailand a COVID-19 related skin rash with petechiae was initially misdiagnosed as Dengue. 31 Jimenez-Cauhe et al. 32 described a patient with erythemato-purpuric, millimetric, coalescing macules in flexural regions. In this case the rash appeared after three days he had started a therapy with hydroxychloroquine and lopinavr/ritonavir. 

Very recently, an association between SARS-CoV-19 and Kawasaki syndrome has been reported, 37-38 an acute vasculitis of childhood, which can complicate with heart disease, mostly in developed countries. Such an association may corroborate the occurrence of an endothelial damage associated with SARS-CoV-19 infection. 

The urticarial-like pattern has been described as a slightly pruritic disseminated erythematous skin rash that healed in few days. 40 In the study by Galvan Casas et al.

This article is protected by copyright. All rights reserved Distinct cutaneous clinical patterns have been associated with COVID-19. They appear at different times in the disease course, and are associated with different duration, severity and prognosis. The different patterns usually do not coexist in the same patient and patients who develop more than one pattern are very uncommon. 14 Among exanthema patterns, varicella-like type is an early and quite specific skin manifestation of SARS-CoV-2 infection and could therefore represent a useful clue in asymptomatic or mild symptomatic patients. 13 It may be distinguished from a typical varicella exanthema since it is characterized by the presence of papules (which do not always evolve into vesicles), and histologically is not associated with a large intraepidermal blister, with only few acantholytic keratinocytes showing characteristic viropathic effects. Moreover, itching is only mild or absent. 13 A Tzank test or Varicella-Zoster PCR may be useful for the differential diagnosis. Interestingly, PCR for SARS-CoV-2 from vesicle may show negative results. 37 This may be related to the fact that PCR assays are not standardized for skin testing or the viral load is too low to be detected. Nonetheless, this finding suggests that varicella-like vesicles in COVID-19 patients are probably not contagious. Other than varicella, differential diagnoses may include dermatologic manifestations of herpes simplex, erythema multiforme, autoimmune bullous diseases such as dermatitis herpetiformis and bullous pemphigoid.

This article is protected by copyright. All rights reserved Urticarial and maculopapular exanthema might not be very helpful for diagnosis, as these are common and may have many different causes. Drug reactions may be an important and challenging differential diagnosis. Other differential diagnoses include acute febrile neutrophilic dermatosis (Sweet syndrome), acute urticaria and erythema multiforme.

Among vascular patterns, pseudo-chilblain may look like perniosis, and as they appear late in the disease progression and are less commonly associated with virologic confirmation, it is possible that they are not immediately related with COVID-19. 25 The differential diagnoses include local trauma, Raynaud phenomenon, acrocyanosis, erythromelalgia and purple toe syndrome associated with oral anticoagulant exposure. Overall, pseudo-chilblain and vesicular lesions may represent the most common and characteristic skin manifestations of COVID-19. However, since pseudo-chilblain lesions more commonly appear later during the disease course and are not associated with severe disease, they might be more useful as epidemiological markers than for diagnosis. [43] [44] Accepted Article This article is protected by copyright. All rights reserved Many issues should be addressed including the dynamic of viral load and its relation with the skin rash. The rash may represent an important clue to determine the optimal timing (before, during, or after the skin rash) to collect the samples for molecular identification.

An important question is whether the dermatological manifestations in COVID-19 may have any impact on the prognosis and consequent treatment of the disease. In this regard, it is unclear if the cutaneous manifestations of SARS-CoV-2 infection are the result of an aberrant immune response and consequently could predispose to systemic immune mediated diseases. 43 One may argue that the immunological response may sustain, not only an acute inflammatory reaction, but also the development of a late/chronic phase of an autoimmune post-infection process characterized by the absence of the infectious agent. In this case, the mechanisms which might be operative may include molecular mimicry and/or epitope spreading and the induction of an autoimmune process related to concomitant host and environmental factors. 45 Lastly, other skin manifestations to be considered are the adverse drug reactions to the drugs prescribed for the treatment of COVID-19 including hydroxychloroquine ( Figure 2 ).

Whether SARS-CoV-2 infection can directly cause a worsening of pre-existing chronic inflammatory diseases such as psoriasis or atopic dermatitis remains to be determined.

Dermatology's outlook in the COVID-19 pandemic is multidimensional. It is important to make clinicians aware of the spectrum of dermatological manifestations of SARS-CoV-2 infection, improving viral testing and clinical management.

WHO Declares COVID-19 a Pandemic

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Viral exanthem in COVID-19, a clinical enigma with Accepted Article This article is protected by copyright. All rights reserved biological significance

Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome

COVID-19 and Cutaneous manifestations

Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S

Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies

Cutaneous manifestation of COVID-19 in images: a case report

Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19

Did Whatsapp® reveal a new cutaneous COVID-19 manifestation?

Teledermatology for COVID-19 cutaneous lesions: substitute or supplement?

Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22

Accepted Article This article is protected by copyright. All rights reserved patients

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Cutaneous lesions in a patient with COVID-19: are they related?

A clinicopathological study of 8 patients with COVID-19 pneumonia and a late-onset exanthema. J Eur This article is protected by copyright. All rights reserved 22

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Acral cutaneous lesions in the Time of COVID-19

Vascular skin symptoms in COVID-19: a french observational study

Chilblains in children in the setting of COVID-19 pandemic

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic

Screening and Severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain

COVID-19 can present with a rash and be mistaken for dengue